CMS Proposes Rule for Future Medicare Drug Price Negotiations
What's happening
The Centers for Medicare & Medicaid Services proposed new rules governing Medicare drug-price negotiations scheduled for 2029. The proposal outlines how future rounds of the federal drug-pricing program would operate under the Inflation Reduction Act.
What's changing / Business impact
Drug manufacturers, insurers, and investors are closely watching because negotiated prices could significantly affect future pharmaceutical revenue. The proposal provides additional clarity on how the government intends to implement future negotiation rounds.
Why this matters
For decades, Medicare was largely prohibited from negotiating drug prices directly. The new program represents one of the most significant changes to U.S. pharmaceutical pricing policy in years. Supporters argue it will reduce costs for patients and taxpayers, while critics worry it could affect incentives for drug innovation.